In the News

Find articles and press on AgeneBio and research updates regarding hippocampal overactivity and aMCI.

April 30, 2015

PODCAST: Promise Shown in Different Approach to Alzheimer’s

The Bio Report

AgeneBio is developing drugs to treat the pre-dementia stage of Alzheimer’s disease, and other neurological and psychiatric conditions. The company announced encouraging mid-stage results for its lead therapeutic, which works by quieting hyperactivity in the hippocampus portion of the brain,…

April 1, 2015

An Epilepsy Drug to Prevent Cognitive Decline?

Medscape

An atypical antiepilepsy drug is being investigated for a possible role in treating patients with mild cognitive impairment (MCI). A new study shows that low doses of levetiracetam reduced the overactivation in subregions of the hippocampus that have been linked…

March 17, 2015

Could epilepsy drug help treat Alzheimer’s disease?

NHS Choices

A drug commonly used to treat epilepsy could help “slow down” the progress of Alzheimer’s disease, reports The Daily Express. According to the news story, the drug levetiracetam was shown to “help restore brain function and memory”. The story is…

March 12, 2015

Agenebio’s AGB101 enroute to phase III on back of aMCI phase II

BioWorld Today

Trying to translate discovery research and early clinical data into phase III success has proved the bane for drug developers working in Alzheimer’s disease. But executives at Agenebio Inc., which is gearing up to start a phase III study in…

March 11, 2015

New Drug Approach May Delay Alzheimer’s Dementia

Nature World News

A new drug approach helped restore the memory of elderly patients who are at high risk for dementia due to Alzheimer’s, and may potentially delay the onset of this debilitating disease, according to new research.

March 11, 2015

AgeneBio scouts deals and dollars ahead of Alzheimer’s PhIII

Fierce Biotech

A small biotech spinout from Johns Hopkins has published its data from a midstage study of a new Alzheimer’s drug that it’s planning to get into a late-stage study. And AgeneBio, founded by Johns Hopkins investigator Michela Gallagher, says the…